Global University Venturing

TU Munich spinout Artisense has developed artificial intelligence-based computer vision aimed at a range of applications, including autonomous driving.

The reputations of Hebrew University and Hadassah Medical Center are expected to attract private investors as limited partners.

Cambridge Epigenetix has now raised $56.5m from investors including the university and Alphabet’s GV for its epigenetics-powered diagnostic platform.

The online education services provider has raised an undisclosed amount of funding at a $1.1bn valuation, adding Mooc-CN to its shareholders.

Synthorx's artificial genetic DNA pairings are expected to support the administration of an immuno-oncology drug previously hindered by safety issues.

The Trinity College Dublin spinout is targeting a form of prostate gland enlargement with a device that could be installed in under 15 minutes.

The first series A tranche will help commercialise a remedy for metabolic disorders and inflammatory conditions resulting from cardio-metabolic problems.

Cambridge spinout Crescendo Biologics has secured $70m in an IP Group and EMBL Ventures-backed round.

The accelerator will connect AbbVie scientists with the lab of Kyriacos Nicolaou, pioneer of an approach for replicating natural molecules with cancer-fighting qualities.

The UCL spinout has secured an additional licence to a protein that aims to reduce side effects associated with its Car T immuno-oncological approach.

Iluminos will commercialise compounds with the potential to combat neurodegenerative diseases such as Alzheimer's.